Science
Novartis Heart Drug Slashes Lp(a) by 78% — Yet Fails to Prevent Heart Attacks
Pelacarsen cut the blood particle lipoprotein(a) by 78% — but after nearly five years, patients were no less likely to…
Pelacarsen cut the blood particle lipoprotein(a) by 78% — but after nearly five years, patients were no less likely to…